In a Phase Ib upgrade/expansion study, LXH254 was evaluated in conjunction with trametinib among patients grappling with advanced/metastatic non-small cell lung cancer harboring KRAS or BRAF mutations and NRAS-mutated melanoma (NCT02974725). Here, NRAS is linked to non-small cell lung carcinoma.